Background and aims: Erroneous thymic selection of developing T lymphocytes may be responsible for the expansion of self reactive T cells or may contribute to the absence of regulatory T cells important in controlling peripheral inflammatory processes. Colitis in bone marrow (BM) transplanted Tge26 mice is induced by abnormally activated T cells developing in an aberrant thymic microenvironment. We investigated the protective role of regulatory CD4 + CD25 + T cells in this model. Methods: BM from (C57BL/66CBA/J) F1 mice was transplanted into specific pathogen free Tge26 mice (BM)Tge26). Transplanted mice received no cells (control), sorted CD4 + CD25 + , or CD4 + CD25 2 cells from mesenteric lymph nodes (MLN) of normal mice. MLN cell subsets were analysed using membrane markers. Cytokine secretion of MLN cells was measured using intracellular cytokine staining and cytokine secretion in anti-CD3 stimulated cell cultures. Colitis was measured by histological scores. T he immune system of the distal intestine must discriminate between harmful foreign antigens and innumerable antigens from the complex resident bacterial flora. Under normal circumstances, immunological tolerance toward the commensal enteric bacterial flora prevents continuous intestinal inflammation. 1 2 There is compelling evidence from both human and animal models that this controlled homeostatic immune response is lost in genetically susceptible hosts that develop chronic immune mediated colitis. 3 4 We and others have shown that activation of T cells reacting against the resident bacterial flora is a key pathogenic mechanism in rodent models of chronic colitis and in humans. [5] [6] [7] The factors leading to the unrestrained activation of T cells have been a focus of recent investigations.
The normal CD4 + T cell population contains both T cell subsets responsible for the induction of inflammation and other T cells that confer suppression. The immunosuppressive activity is contained predominantly within the CD4 + T cell population that constitutively expresses the interleukin (IL)-2R a-chain (CD25). 8 Transfer of regulatory CD4 + CD25 + cells in different experimental settings demonstrated their pivotal role in the maintenance of self tolerance, 9 in regulating peripheral T cell homeostasis, 10 11 in transplantation tolerance, 12 and in graft versus host protection after bone marrow (BM) transplantation. 13 14 The thymus has been identified as the place where regulatory T cells (Treg cells) develop 15 16 and a normal thymic architecture is necessary for adequate selection of Treg cells. 17 By allowing selective transfer of T cell subsets, spontaneously mutated and transgenic mice lacking adult T lymphocytes (SCID, Rag, and Tge26, respectively) can provide insights into the pathogenic role of different T cell subsets in the intestinal inflammatory process. A growing body of evidence suggests that regulatory CD4 + CD25 + T cells play an important role in the prevention and treatment of intestinal inflammation in SCID mice. In this model, colitis develops after transfer of naïve CD4 +
CD45RB
hi T cells and can be prevented by co-transfer of the naturally activated CD45RB low subset. 18 19 Because colitis in SCID mice can only be induced by transfer of adult T lymphocytes but not by BM transplantation, 20 21 interaction of thymus dependent T cell development and Treg cells cannot be studied in the context of colitis.
The immunopathogenesis of experimental colitis in Tge26 mice is substantially different. Tge26 mice are transgenic for the human CD3e gene. This results in very early arrest of T cell development which prevents the induction of a normal thymic microenvironment. 22 BM transplantation from syngenic wild-type mice into Tge26 mice (BM)Tge26 mice) restores the T cell compartment. However, T cell development and selection in the abnormally structured thymus are profoundly compromised. Consequently, aggressive CD4 + T cells develop while peripheral CD8 + cells are almost absent.
CD4
+ cells are characterised by low CD45RB high expression and by secretion of a T helper 1(Th1) cytokine profile consisting of interferon c (IFN-c) and tumour necrosis factor a (TNF-a). 23 These cells cause severe colitis. [23] [24] [25] [26] To date, the mechanisms underlying the development of aggressive T cells in the abnormal thymus in Tge26 mice have only been partially elucidated. Failure of the thymus to negatively select aggressive T cells is one possibility. Alternatively, a defect of positive selection of Treg cells in the thymus may cause loss of control. The latter hypothesis is more compatible with experiments in which transplantation of a normal thymus into BM)Tge26 mice with a persistent abnormal thymus prevented the development of colitis. 23 However, direct evidence for a key role of absent Treg cells in the pathogenesis of colitis in Tge26 mice is missing and such cells need to be further characterised.
The purpose of the present study was to investigate whether defective selection of CD4 +
CD25
+ Treg cells in the compromised thymic environment of Tge26 mice is responsible for the development of colitis after BM transplantation. Specifically, we sought to determine whether the aberrant activity of T cells derived from the thymus of BM)Tge26 mice can be corrected by regulatory CD4
+

CD25
+ cells and to assess the mechanisms by which this correction is mediated.
MATERIALS AND METHODS
Mice
Normal (C57BL/66CBA/J) F1 mice were purchased from Taconic M&B (Bomholtvej, Denmark). Tge26 mice, generated by overexpression (.30 copies) of the full length human CD3e gene, were established by sibling breeding of animals on the C57BL/66CBA/J background under specific pathogen free (SPF) conditions at our local animal facility. All mice were 8-16 weeks old.
BM purification and transplantation BM cells were harvested from tibias and fibulas of (C57BL/6 6 CBA/J) F1 mice. To avoid allorecognition of the Tge26 recipients, donor BM cells were depleted of mature T cells. This was achieved by two rounds of complement mediated lysis using anti-Thy1.2 monoclonal antibody (clone 30-H12; BD PharMingen, San Diego, California, USA) on ice for 30 minutes followed by rabbit complement (Cedarlane) at 37˚C for 45 minutes. Thereafter, less than 0.1% CD4 + and 0.2% CD8 + T cells were present in the BM inoculum, as determined by flow cytometry. BM recipients were pretreated with 150 mg/kg 5-fluorouracil (Gry-Pharma, Germany) intraperitoneally 48 hours before engraftment with 5610 6 BM cells resuspended in sterile phosphate buffered saline and injected intraperitoneally into SPF Tge26 recipients.
Antibodies
The following antibodies were used for cell purification: antimouse CD45R (B220) Microbeads (clone RA3-6B2) and antimouse CD8a (Ly-2) Microbeads (clone 53-6.7) (Miltenyi Biotec, Bergisch Gladbach, Germany); PE conjugated antimouse CD4 (clone GK1.5) and fluorescein isothiocyanate (FITC) conjugated antimouse CD25 (IL-2 receptor a chain, p55) (clone 7D4) were used for FACS sorting. FITC conjugated antimouse CD4 (clone GK1.5) and PE conjugated antimouse CD8a (Ly-2) (clone 53-6.7) were used for FACS analysis after T cell depletion in BM and for T cell analysis in sacrificed mice. FITC conjugated antimouse IL-10 (clone JES5-16E3) and FITC conjugated antimouse TNF-a (clone MP6-XT22) were used for intracellular cytokine staining.
For cell stimulation, antimouse CD3 (CD3e chain, clone 145-2C11), and for IL-10 staining antimouse CD28 (clone 37.51), were used.
Purification of T cell subsets
For CD4 +
CD25
+ and CD4 + CD25 2 cell transfer, cells were isolated from mesenteric lymph nodes (MLN). Cells were washed in RPMI l640 (Gibco, Grand Island, New York, USA), supplemented with 5% heat inactivated fetal bovine serum (Greiner, Germany) and antibiotics/antimycotics (penicillin G, streptomycin, and amphotericin B) (Sigma Chemical Co., St Louis, Missouri, USA), and resuspended in MACS buffer. Cells were depleted of CD8 + and B220 + cells by negative selection using antimouse coated Microbeads (Miltenyi Biotec). The resulting CD4
+ enriched cells were stained with PE conjugated anti-CD4 and FITC conjugated anti-CD25 monoclonal antibodies. Subsets of CD4 + cells were generated by two colour sorting on a BD FACS Vantage SE/DiVa Option. All populations were .98% pure on reanalysis.
T cell transfer experiments CD4
+
CD25
+ and CD4 + CD25 2 T cells were separately resuspended in phosphate buffered saline and injected intraperitoneally into BM)Tge26 recipients. The injections were done one week after BM transplantation. One group of mice received CD4
+ CD25 + cells on the day of BM transplantation. Mice were observed daily and weighed at least twice a week. Mice showing clinical signs of severe disease were sacrificed (4-5 weeks after BM transplantation). Healthy recipients were sacrificed six weeks after BM transplantation.
Histological examination
Colons were fixed in buffered 5% formalin. Thick paraffin embedded sections (2 mm) were stained with haematoxylin and eosin. Inflammation was scored in a blinded fashion on a scale from 0 to 4, representing no change to severe changes, as previously described. 24 
Flow cytometry
Isolated unseparated MLN cells were stained with FITC labelled antimouse CD4 and PE labelled antimouse CD8. Intracellular staining for TNF-a and IL-10 was performed using MLN cells five hours after stimulation with immobilised anti-CD3 for TNF-a and in addition anti-CD28 for IL-10. Brefeldin A (Sigma) was added two hours after culture initiation. Cells were first stained with antimouse CD4 PE. Before staining, cells were fixed with 2% paraformaldehyde (Riedel-de Haen, Seelze, Germany) and permeabilised using 0.2% saponin (Sigma). T cells were analysed on a FACscan flow cytometer (Becton Dickinson, Heidelberg, Germany) using CellQuest software. Isotype matched control antibody staining served as the zero value.
Cytokine assays
Transforming growth factor b (TGF-b), IL-10, IFN-c, and TNF-a were measured in MLN cell culture supernatants prepared as previously described 5 and analysed using standard ELISA techniques (R&D Systems, Germany). 25 Concentrations of cytokines were established in duplicated culture supernatants by comparison with standard curves. Limits of detection are 7 pg/ml of TGF-b, 4.0 pg/ml of IL-10, 2 pg/ml of IFN-c, and 5.1 pg/ml of TNF-a.
Statistical analysis
Parametric data were analysed by the Student t test and nonparametric data by the Mann-Whitney test. A p value of ,0.05 was considered significant.
RESULTS
Regulatory CD4
+ CD25 + cells are reduced in BM transplanted Tge26 mice We first investigated whether regulatory CD4
+ CD25 + cells were reduced in BM)Tge26 mice. Therefore, MLN cells of BM)Tge26 mice were analysed by flow cytometry in comparison with wild-type mice 4-6 weeks after BM transplantation. The percentage of MLN cells that expressed both CD4 and CD25 was lower in Tge26 mice with colitis than in healthy wild-type mice (colitic 1.5 (1.1)%; wild-type 2.6 (1.0)%; p,0,05) (fig 1) . 
CD25
2 cells substantially increased the CD4/CD8 MLN cell ratio (table 1) . Taken together, these data suggest that regulatory CD4
+ CD25 + cells reduce the pathogenic CD4 + T cells in BM)Tge26 mice and correct imbalances of peripheral T cell differentiation.
+ regulatory cells reduce TNF-a producing cells dose dependently In the BM)Tge26 mouse model, CD4
+ cells operate via a Th1 cytokine profile with a predominance of TNF-a and IFN-c production. 26 27 Therefore, we studied the effect of CD4 
+ cells were transferred on the same day as BM (data not shown). In contrast, mice reconstituted with CD4 +
2 cells started to lose weight two weeks after BM transplantation (fig 3) and showed clinical signs of wasting and colitis (for example, piloerection, hunching, bloody diarrhoea). Within this group, two mice died two weeks after BM transplantation. The control group of only BM)Tge26 mice started to show clinical signs of inflammation, including weight loss four weeks after transplantation, confirming previous results (fig 3) . Histopathological analysis of the colon from untreated BM)Tge26 mice showed inflammation in all parts, with the most severe inflammation in the distal colon and caecum. This was characterised by leucocyte infiltration in the mucosa and submucosa, prominent epithelial hyperplasia, loss of goblet cells, occasional crypt abscesses, and ulcerations (distal colon score 2.6 (0.5)) (fig 4, 5B) . Transfer of 3610 5 
CD4
+ CD25 + cells led to an almost normal colon architecture with only a mild increase in leucocyte infiltration but no other signs of colitis (distal colon score 0.3 (0.3)) (fig 4, 5C) . Lower transfer numbers of CD4 +
CD25
+ cells failed to prevent colitis (distal colon score 2.8 (0.4)) (fig 4, 5D 
+ cells downregulate the immune response predominantly by production of TGF-b.
DISCUSSION
It is unclear whether the development of colitis in BM)Tge26 mice results from failure of negative selection of aggressive T cells in the abnormal thymus or from insufficient production of thymic dependent regulatory T cells. Our findings provide strong evidence for defective function of regulatory CD4 + CD25 + T cells in the pathogenesis of bowel inflammation in this model. Firstly, CD25
+ expression on CD4
+ cells in the MLN was significantly lower in BM)Tge26 mice with colitis than in healthy wild-type animals. Interestingly, our findings correspond to recent results in IBD patients in whom intestinal CD4 + CD25 + cells were decreased in active disease. 31 Moreover, co-administration of CD4 
CD25
+ cells has been demonstrated in SCID and Rag mice. [32] [33] [34] However, the immunological mechanisms of colitis in these models differ from the BM)Tge26 colitis model. Transfer of the naïve CD4 + CD45RB high T cell subset from wild-type mice into SCID/Rag mice induces colitis in the recipients. This can be prevented by co-injection of the antigen experienced subset of CD4 + CD45RB low T cells. 18 The CD25 + population comprises the inhibitory subset of CD4 + CD45RB low T cells. 10 In contrast, colitis in Tge26 mice is driven by CD4 + CD45RB low cells, 5 23 and CD45RB low cells from colitic Tge26 mice could transfer severe colitis to untransplanted Tge26 recipients. 23 + CD45RB low cells into SCID mice can also induce colitis. 35 However, colitis development was still different from the Tge26 model because it developed only when anti-IL-10R monoclonal antibody was co-administered. Furthermore, the ability of CD4 + CD45RB low cells to induce inflammation was significantly reduced when these cells were isolated from germ free mice. In contrast, in the Tge26 model, the colitis inducing CD4 + CD45RB low cells are bacteria specific without further manipulation and have the functional capacity to induce colitis when transferred to specific pathogenic free recipients even when isolated from germ free BM)Tge26 mice. 5 Based on our present study we speculate that the development of bacteria specific T cells may be due to the aberrant thymic selection of regulatory cells.
Differences in Treg cell mediated protection of colitis in the SCID mouse versus the Tge26 mouse is also visible in the number of Treg cells necessary to prevent inflammation. While Read and colleagues 32 reported that 5610 4 CD4
+ CD25 + cells were sufficient to prevent colitis in SCID mice, we had to transfer a minimum of 3610 5 cells into BM)Tge26 mice for protection. In the Tge26 mouse a high number of very activated T cells develop after bone marrow transplantation. Thus differences in the number and also in the proinflammatory potential of colitic T cells in the two models might be responsible for the different Treg cell numbers necessary for the effects observed.
Our studies examined the mechanisms by which CD4 +
+ T cells prevented colitis. Protection in our experiments was seen as early as four weeks after cell transfer in contrast with the SCID mouse model in which complete protection became manifest 10 weeks after cell transfer. 33 Delayed protection in SCID mice was interpreted as a sign that Treg cells suppress the inflammatory response via an indirect mechanism. 33 Foussat et al proposed that Treg cells function indirectly by enhancing differentiation of IL-10 secreting T cells. 36 Asseman et al suggested that IL-10 secretion by CD4 + CD25 + T cells is not an absolute requirement for inhibition of colitis in the SCID model because CD4
+ cells from IL-102/2 mice inhibited colitis. 35 We detected only minimal and almost identical IL-10 on intracellular staining of MLN CD4 + cells from BM)Tge26 mice and BM)Tge26 reconstituted with either CD4 + 25 + or CD4 
+ cells in this model. TGF-b has been shown to be the key immunosuppressive cytokine in CD4 + CD25 + regulatory cells in various disease models. 29 37 38 Recently, it was demonstrated that TGF-b also converted CD4 + CD25 2 naïve T cells to CD4
These cells expressed the transcription factor Foxp3 which is associated with the development of Treg cells. 40 41 In vivo data demonstrated that Foxp3 expressing Treg cells prevented colitis in SCID mice. 40 In our experiments, TGF-b was 42 showed that CD8 + T cells induced CD4 + CD8 + CD25 + thymocytes. These double positive thymocytes are absent in BM)Tge26 mice. 22 We speculate that Treg cell induced CD8
+ cells act in a positive loop inducing the development of double positive thymocytes, thereby promoting the normalisation of the Tge26 thymic architecture and T cell development.
In summary, our experiments show that CD4 + CD25 + T cells play an important role in the prevention of intestinal inflammation in the Tge26 colitis model. CD4
+
CD25
+ T cell transfer resulted in a substantial modification of the MLN T lymphocyte subsets. This may identify a possible new mechanism by which Treg cells induce immune suppression in experimental colitis.
Clinical Evidence-Call for contributors
Clinical Evidence is a regularly updated evidence-based journal available worldwide both as a paper version and on the internet. Clinical Evidence needs to recruit a number of new contributors. Contributors are healthcare professionals or epidemiologists with experience in evidence-based medicine and the ability to write in a concise and structured way.
Areas for which we are currently seeking authors: N Child health: nocturnal enuresis N Eye disorders: bacterial conjunctivitis N Male health: prostate cancer (metastatic) N Women's health: pre-menstrual syndrome; pyelonephritis in non-pregnant women However, we are always looking for others, so do not let this list discourage you.
Being a contributor involves:
N Selecting from a validated, screened search (performed by in-house Information Specialists) epidemiologically sound studies for inclusion. N Documenting your decisions about which studies to include on an inclusion and exclusion form, which we keep on file.
N Writing the text to a highly structured template (about 1500-3000 words), using evidence from the final studies chosen, within 8-10 weeks of receiving the literature search. N Updating the text every six months using any new, sound evidence that becomes available.
The Clinical Evidence in-house team will conduct the searches for contributors; your task is simply to filter out high quality studies and incorporate them in the existing text.
N To expand the topic to include a new question about once every 12-18 months.
If you would like to become a contributor for Clinical Evidence or require more information about what this involves please send your contact details and a copy of your CV, clearly stating the clinical area you are interested in, to Klara Brunnhuber (kbrunnhuber@ bmjgroup.com).
Call for peer reviewers
Clinical Evidence also needs to recruit a number of new peer reviewers specifically with an interest in the clinical areas stated above, and also others related to general practice. Peer reviewers are healthcare professionals or epidemiologists with experience in evidence-based medicine. As a peer reviewer you would be asked for your views on the clinical relevance, validity, and accessibility of specific topics within the journal, and their usefulness to the intended audience (international generalists and healthcare professionals, possibly with limited statistical knowledge). Topics are usually 1500-3000 words in length and we would ask you to review between 2-5 topics per year. The peer review process takes place throughout the year, and our turnaround time for each review is ideally 10-14 days.
If you are interested in becoming a peer reviewer for Clinical Evidence, please complete the peer review questionnaire at www.clinicalevidence.com or contact Klara Brunnhuber (kbrunnhuber@bmjgroup.com).
